Legal Representation
Attorney
John M. Mueller
Application History
28 events| Date | Code | Type | Description |
|---|---|---|---|
| Jun 23, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jun 23, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| May 29, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| May 29, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| May 29, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| May 29, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| May 29, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| May 29, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| May 19, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN |
| May 19, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| May 19, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED |
| May 19, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN |
| May 19, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| May 19, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED |
| May 16, 2025 | DOCK | D | ASSIGNED TO EXAMINER |
| May 16, 2025 | DOCK | D | ASSIGNED TO EXAMINER |
| Mar 4, 2025 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Mar 4, 2025 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED |
| Mar 4, 2025 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED |
| Mar 4, 2025 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Mar 4, 2025 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED |
| Mar 4, 2025 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED |
| Feb 11, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Feb 11, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Feb 11, 2025 | NWAP | I | NEW APPLICATION ENTERED |
| Feb 11, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Feb 11, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Feb 11, 2025 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations and substances for the treatment of respiratory conditions and disease, namely, chronic obstructive pulmonary disease, cystic fibrosis and asthma
Class 042
Scientific research for medical purposes, namely, the research and development of pharmaceutical preparations for the treatment of respiratory conditions and disease, in particular, chronic obstructive pulmonary disease, cystic fibrosis and asthma
Class 044
Medical treatment services in the field of respiratory conditions and disease, namely, chronic obstructive pulmonary disease, cystic fibrosis and asthma; provision of medical information and services in the field of respiratory conditions and disease, namely, chronic obstructive pulmonary disease, cystic fibrosis and asthma
Classification
International Classes
005
042
044